Kura Oncology Elevates Leadership Team Amid Key Changes
Mollie Leoni, M.D., has received a significant promotion to Chief Medical Officer at Kura Oncology, Inc., a company dedicated to pioneering precision medicine for cancer care.
Leadership Changes Unveiled
The announcement, released from San Diego, highlights further advancements within the company. In addition to Dr. Leoni's promotion, Francis Burrows, Ph.D., has stepped up as Chief Scientific Officer. This restructuring comes following Stephen Dale, M.D.’s decision to step down as Chief Medical Officer as he seeks to focus on his health.
Recognizing Contributions
Troy Wilson, Ph.D., J.D., President and CEO of Kura, expressed heartfelt gratitude towards Dr. Dale for his invaluable contributions. His leadership was pivotal in driving Project Optimus and advancing ziftomenib through crucial study phases.
Mollie Leoni: A Proven Leader
Dr. Leoni joined Kura in early 2020, initially serving as Vice President of Clinical Development. Her trajectory has showcased her remarkable capabilities and expertise in oncology, culminating in her new role. Dr. Leoni's leadership has been instrumental in the ziftomenib program, a therapy on the brink of transformative potential for patients battling acute myeloid leukemia (AML).
Scientific Innovations Under Dr. Burrows
With over two decades of experience, Dr. Burrows brings a wealth of knowledge in drug discovery. His commitment to advancing cancer treatment has made substantial impacts, notably leading Kura’s innovative initiatives in adenocarcinomas and other tumors.
Kura's Innovative Endeavors
Kura Oncology has built a robust pipeline of small molecule drug candidates that target specific cancer signaling pathways. The standout candidate, ziftomenib, is not only groundbreaking but has also achieved the Breakthrough Therapy Designation from the FDA for the treatment of relapsed or refractory NPM1-mutant AML.
Collaborations and Future Directives
Recently, Kura embarked on a vital global collaboration with Kyowa Kirin Co., Ltd. to enhance the development of ziftomenib for hematologic malignancies. With clinical trials underway and promising results, Kura is thrilled about the potential submission for a New Drug Application.
Understanding Kura's Commitment to Cancer Care
The vision at Kura Oncology extends beyond just advancing treatments; it embodies patient-centric approaches that bring hope to those affected by cancer. The firm’s focus on innovative combinations and its pipeline’s diversity reflects its relentless pursuit of breakthroughs.
Kura's Pipeline Overview
In addition to ziftomenib, Kura is evaluating KO-2806, a next-gen farnesyl transferase inhibitor currently undergoing extensive trials. The potential for combination therapies also looms large, with various phases ongoing to ensure optimal patient outcomes.
Frequently Asked Questions
What recent promotions occurred at Kura Oncology?
Mollie Leoni was promoted to Chief Medical Officer, while Francis Burrows was named Chief Scientific Officer, succeeding Stephen Dale.
What is ziftomenib?
Ziftomenib is an investigational oral menin inhibitor targeting NPM1-mutant acute myeloid leukemia, and it has received Breakthrough Therapy Designation from the FDA.
What kind of cancer does Kura primarily focus on?
Kura focuses on developing precision treatments primarily for cancers such as acute myeloid leukemia and solid tumors.
What collaboration has Kura recently announced?
Kura entered a strategic collaboration with Kyowa Kirin Co., Ltd. to further develop and commercialize ziftomenib for AML and related hematologic conditions.
Who can I contact for media inquiries about Kura Oncology?
For media inquiries, Cassidy McClain, Vice President at Inizio Evoke Comms, can be reached at (619) 849-6009.
